Argos to present on HIV treatment at conference
Argos is dedicated to developing and commercializing fully personalized immunotherapies for treating cancer and infectious diseases. The company uses the Arcelis technology platform for these developments.
The representative will be Irina Tcherepanova, the director of molecular biology at Argos. The event will be hosted by the Vancouver Convention Centre in Vancouver, British Columbia, Sunday through Wednesday.
Tcherepanova is scheduled to participate in the conference’s roundtable discussion about combination therapy trials. The discussion will take place as part of the event’s symposium, “Towards an HIV Cure,” Saturday. Her post presentation is titled “Polyvalent immune responses correlate with lower number of HIV-infected CD4 T cells in chronically infected subjects treated with autologous RNA-pulsed DC therapy,” which is Tuesday.
The IAS Conference will feature the most recent advances in HIV science, which includes the clinical, basic and prevention research of the industry. This event unites a broad variety of HIV professionals who travel from locations around the world to attend the conference.